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phase of the myucardial infarction a
index arrhythmia 56 weeks after infarction 
tients with a history of myocardial infarction 
1 year mortality rate of 81% if their index in 
the anterior wall, even when the patient w 
hemodynamic class I or II during the suba 
infarction. Both the documentatloil bythe Dut 
this poor prognosis despite conventio,lal ther 
findings of the Cardiac Arrhythmia Suppression Trial 
(CAST) study (1) emphasize the need to reassess current 
practice in risk stratification a d management of hese pa- 
tients. 
Several investigations (3), including the Dutch study 0, 
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served for those patients w
no randomized controlled 
nts are available to assess 
infarction (9) in patients without heart failure, may have a 
potential therapeutic role, particularly if myocard~a~ ische- 
s. la view of the prognostic 
icular function, it is important 
to assess the effects of interventions designed to preserve 
myocardium in patients with poor function. Clea 
intervention has been more successful in this rega 
early repetfusion (IO). Indeed, a milieu for reentrant ventric- 
ular tachycardia assuggested bythe presence of late poten- 
tials is rarely seen in patients with successful thro 
(I I). as has been corroborate ressively low 
incidence of Late mortality in fo:sow-up of 
tients (12). In the majority of patients with 
tion who do not undergo thrombolysis with sub- 
sequent reperfusion, vasodilators have significantly reduced 
short-term ortality (13). The need to develop an optimal 
strategy for risk stratification is perhaps greatest inassessing 
the role of the automatic implantable cardioverter- 
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defibrillator (AICD) (14), particularly because its use cur- 
rently requires athoracotomy for implantation. 
Conclusions. The Dutch study (2) emphasizes the impor- 
tance of optimizing risk stratification a d carrying out pro- 
spective studies to assess a variety of medical treatment 
strategies, including the automatic implantable cardioverter- 
defibrillator (13), in patients with ventricular tachycardia or
fibrillation late after myocardial infarction. The latter strat- 
egy will be even more applicable if transvenous systems 
become available. Inall likelihood, the alarmingly high late 
mortality rate after myocardial infarction in the high risk 
subgroup ofthe Dutch study has many causes, and preven- 
tive efforts may have to be multipronged rather than limited 
to conventional antiarrhythmic management. 
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